Some Ebola guidelines questioned

Experts questions questioning calls for suspending certain routine lab tests


Experts are questioning aspects of some of the Ebola guidelines that go beyond current Centers for Disease Control and Prevention (CDC) recommendations, especially those that call for suspending certain routine lab tests, according to an article on Infection Control Today.

A commentary in the journal Transfusion suggests that most individuals with suspected Ebola will have a fever due to another cause, and forgoing such testing may compromise patients' health more than any reduction in the risks to laboratory personnel.

The article says that all laboratory directors must work with infection control and safety experts to evaluate their hospital policies on potentially infectious patients to provide a safe environment.

Read the article.

 

 



December 12, 2014


Topic Area: Safety


Recent Posts

Building Sustainable Healthcare for an Aging Population

Traditional responses — building more primary and secondary care facilities — are no longer sustainable.


Froedtert ThedaCare Announces Opening of ThedaCare Medical Center-Oshkosh

The organization broke ground on the health campus in March 2024.


Touchmark Acquires The Hacienda at Georgetown Senior Living Facility

The facility will now be known as Touchmark at Georgetown.


Contaminants Under Foot: A Closer Look at Patient Room Floors

So-called dust bunnies on hospital room floors contain dust particles that turn out to be the major source of the bacteria humans breathe.


Power Outages Largely Driven by Extreme Weather Events

Almost half of power outages in the United States were caused by extreme weather events.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.